$1.61 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 33 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 23.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $306,498,000 | -36.2% | 4,831,307 | -17.1% | 19.01% | -39.6% |
| DVAX | Sell | DYNAVAX TECHNOLOGIES CORP | $161,652,000 | +39.4% | 8,415,000 | -28.5% | 10.03% | +32.0% |
| New | RAPID MICRO BIOSYSTEMS INC | $155,786,000 | – | 8,434,560 | +100.0% | 9.66% | – | |
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $129,722,000 | +7.5% | 3,700,000 | -34.1% | 8.05% | +1.8% |
| New | ADAGIO THERAPEUTICS INC | $105,060,000 | – | 2,487,207 | +100.0% | 6.52% | – | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC. | $95,065,000 | -12.5% | 3,979,292 | 0.0% | 5.90% | -17.1% | |
| New | NUVALENT INC | $77,302,000 | – | 3,428,014 | +100.0% | 4.80% | – | |
| CCCC | C4 THERAPEUTICS INC | $73,374,000 | +18.1% | 1,642,209 | 0.0% | 4.55% | +11.8% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $62,098,000 | -46.0% | 3,080,237 | 0.0% | 3.85% | -48.9% | |
| ANNX | ANNEXON INC | $60,327,000 | -17.3% | 3,241,628 | 0.0% | 3.74% | -21.7% | |
| PHVS | PHARVARIS N V | $56,392,000 | -4.8% | 3,180,601 | 0.0% | 3.50% | -9.9% | |
| NRIX | NURIX THERAPEUTICS INC | $38,478,000 | +12.9% | 1,284,314 | 0.0% | 2.39% | +6.9% | |
| CRNX | CRINETICS PHARMACEUTICALS | $35,358,000 | +11.7% | 1,679,701 | 0.0% | 2.19% | +5.7% | |
| MRSN | MERSANA THERAPEUTICS INC. | $34,850,000 | -30.6% | 3,695,667 | 0.0% | 2.16% | -34.2% | |
| SYRS | SYROS PHARMACEUTICALS INC | $25,859,000 | -18.0% | 5,785,036 | 0.0% | 1.60% | -22.4% | |
| New | TANGO THERAPEUTICS INC | $24,849,000 | – | 1,921,790 | +100.0% | 1.54% | – | |
| AGLE | Buy | AEGLEA BIO THERAPEUTICS INC | $22,639,000 | +20.5% | 2,847,689 | +5.5% | 1.40% | +14.1% |
| APTX | APTINYX INC | $20,807,000 | -17.3% | 8,891,758 | 0.0% | 1.29% | -21.7% | |
| SLDB | SOLID BIOSCIENCES INC | $18,953,000 | -34.7% | 7,929,918 | 0.0% | 1.18% | -38.2% | |
| MARINUS PHARMACEUTICALS INC | $16,285,000 | -36.6% | 1,431,058 | 0.0% | 1.01% | -40.0% | ||
| SVRA | SAVARA INC | $16,039,000 | -18.8% | 11,622,598 | 0.0% | 1.00% | -23.2% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $12,280,000 | -39.2% | 2,000,000 | 0.0% | 0.76% | -42.4% | |
| XFOR | X4 PHARMACEUTICALS INC | $11,212,000 | -18.6% | 2,119,540 | 0.0% | 0.70% | -22.9% | |
| RACB | RESEARCH ALLIANCE CORP II | $9,850,000 | -2.9% | 1,000,000 | 0.0% | 0.61% | -8.0% | |
| BLUE | BLUEBIRD BIO INC | $7,239,000 | -57.9% | 538,179 | 0.0% | 0.45% | -60.2% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $7,035,000 | -6.2% | 700,000 | 0.0% | 0.44% | -11.4% | |
| New | ARYA SCIENCES ACQUISITN CORP | $4,940,000 | – | 500,000 | +100.0% | 0.31% | – | |
| PANA | PANACEA ACQUISITION CORP II | $4,885,000 | -2.5% | 500,000 | 0.0% | 0.30% | -7.6% | |
| BLSA | BCLS ACQUISITION CORP | $4,856,000 | -5.4% | 487,500 | 0.0% | 0.30% | -10.4% | |
| OMEG | OMEGA ALPHA SPACcl a | $3,894,000 | -2.2% | 400,000 | 0.0% | 0.24% | -7.3% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $3,009,000 | -0.2% | 300,000 | 0.0% | 0.19% | -5.6% | |
| JYAC | JIYA ACQUISITION CORP | $2,925,000 | -1.9% | 300,000 | 0.0% | 0.18% | -7.2% | |
| HLXA | HELIX ACQUISITION CORP | $2,488,000 | -3.9% | 250,000 | 0.0% | 0.15% | -9.4% | |
| BCTG | Exit | BCTG ACQUISITION CORP | $0 | – | -921,790 | -100.0% | -0.69% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC. | $0 | – | -479,605 | -100.0% | -1.52% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.